Scale

Connections to venture capital sources for startups

Provided by: Bio/Med Investor Network

Who’s eligible: Any Emory faculty, staff or students who have early-stage companies in the biomedical, medical technology and health IT spaces

After you’ve launched a company, you can apply to be considered for introduction to investors through the Bio/Med Investor Network.

The network is not a fund; rather, it helps entrepreneurs prepare for fundraising by introducing them to angel investors and advisors, many of whom are successful entrepreneurs themselves.

The Bio/Med Investor Network reviews companies and selects promising deals for initial screening by some of its investor members. The companies that pass the screening process will be invited to present at a member meeting. After that, investor members vote on whether to pursue due diligence on your company.

The typical investment stage target is from $200,000 to $2 million. However, companies outside of these stages of fundraising are also considered.

More about the network >

Research facilities to expand testing, development

Provided by: GRA Core Exchange

Who’s eligible: All Emory research scientists

Regardless of whether you’ve launched or are planning to start a company, you can continue development and/or testing of your potential product in core research facilities across Georgia.

GRA Core Exchange provides Emory researchers with access to sophisticated technology at all participating Georgia universities. So if another university has a core facility, specialized equipment or instrumentation that you need, chances are you can use it.

Gaining access to a core facility is easy. Contact the core of interest to discuss a scope of work and obtain a pricing quote. (Typically, institutions set an external rate that represents the cost of providing the service to those outside the university.)

Once an agreement is reached on your scope of work and pricing, your project can proceed.

In 2019, GRA Core Exchange will post an inventory of available core facilities. For now, you can visit the websites of individual facilities at GRA Core Exchange.

See the participating universities and core facilities >

Connections to private industry

Provided by: Emory Office of Corporate Relations

Who’s eligible: Any Emory entrepreneur who has started a company

As a leading university, Emory has strong and long-standing relationships with corporations. If you’ve formed a startup at Emory, you may benefit from interacting with one or more of these companies.

Emory’s Office of Corporate Relations can help you make the connection. The office serves as the principal liaison with the university’s corporate partners. Its team of professionals can help identify and capitalize on opportunities that serve both your company and a partner corporation.

The connections the Office of Corporate Relations helps you make may generate support for sponsored research or clinical trials. The office may even be able to introduce you to venture capital and angel investors.

A first step is to contact the office and arrange a consultation:

Gayathri Srinivasan Ph.D., Executive Director
404-727-9843

Karl Jennings, Director of Corporate Relations
404-727-3540

Help with developing and testing a medical product

Provided by: Global Center for Medical Innovation (GCMI)

Who’s eligible: Any Emory employee or student seeking to market a medical device

If you’re looking for help taking a medical product from concept to commercialization, GCMI can provide “lifecycle advisory services.”

GCMI’s team is an entire ecosystem of experts – including several biomedical engineers – who work to minimize risk and streamline overall development. They provide:

  • Design and development – from generating initial concepts through transfer to production manufacturing. The design and development team follows a structured, phase-gated process to ensure a disciplined approach. Ask about design and development >
  • Preclinical testing and bioskills training – for developers of medical devices, biologics and pharmaceuticals in 11 therapeutic areas. GCMI’s preclinical contract research organization is GLP-compliant and AAALAC-accredited. Find out more about preclinical training and testing >

Those who use GCMI’s lifecycle advisory services can enter at different points on the commercialization path, from back-of-the-napkin ideas to late-stage preclinical work, regulatory submission and post-market training.

The GCMI team can also help you work through regulatory compliance, clinical practices, intellectual property and healthcare economics, all in a capital-efficient way.

GCMI will provide a cost estimate for the services provided to you prior to beginning work.

Contact GCMI to get started >

Early-stage funding for high-potential startups

Provided by: GRA Venture Fund, LLC

Who’s eligible: Any Emory employee that has launched a company

Startups and young companies engaged in early rounds of venture funding may be selected to receive investment and advice from GRA Venture Fund, LLC.

The fund is an independent, public-private investment fund launched out of the Georgia Research Alliance. It focuses its investment on high-potential companies in science and technology.

The vast majority of young companies receiving GRA Venture Fund investment first participated in GRA’s venture development grant and loan program. However, earlier support from GRA is not a requirement.

Startups do not apply for GRA Venture Fund investment – it’s best to contact Kevin Lei in Emory’s Office of Transfer Technology to learn more.

Learn about GRA Venture Fund >

Funding for established startups

Provided by: Coulter Translational Program

Who’s eligible: Any Emory (or Georgia Tech) employee or student who has launched a company

  • Intellectual property rights must be held (at least in part) by Emory and/or Georgia Tech
  • Requires both a technical PI and an appropriate clinical PI
As described in the “Start” area of our site: The program funds “translational research that addresses unmet clinical needs and will lead to commercial products.” Its primary goal is to “improve patient care through collaborations between clinicians and engineers to commercialize biomedical technologies.”

The Coulter Translational Program typically applies expertise and funding to get new ventures off the ground. However, if a company has already been launched around the invention or discovery, it may not be too late to apply for Coulter Translational Program funding to help get the enterprise off the ground.

The program awards $1.5 million each year to portfolio projects. The amount of each award is determined by the project and its milestones.

Technologies meeting the eligibility criteria are then vetted based on probability of future commercial success. Some features included in this analysis are:
  • Validity of unmet clinical need
  • Competitive landscape
  • Current and future market dynamics
  • Strength and nature of intellectual property
  • Addressability of regulatory risk
  • Understanding of potential reimbursement hurdles
  • High probability of attracting 1) follow-on investor funding or 2) a license to an industry partner within 2-3 years of receiving the award

More about the grants >